Cardiovascular disease (CVD) is an emerging concern for HIV-infected patients. Hyperlipidaemia is a risk factor for CVD and a complication of protease-inhibitor-based antiretroviral therapy, but little is known about its incidence and risk factors in treated patients in resource-limited settings (RLS).
Methods
We conducted a secondary analysis of ACTG A5230 trial in which HIV-infected adults from India, Malawi, Tanzania, Thailand and South Africa, with virological relapse on first-line therapy were initiated on lopinavir/ritonavir (LPV/r) monotherapy. Hyperlipidaemia was a grade 2+ elevated fasting total cholesterol (FTC≥240 mg/dl) or fasting triglycerides (FTG≥500 mg/dl) or calculated low-density lipoprotein cholesterol (LDL≥160 mg/dl) based on measurements at weeks 12, 24, 48, 68 and 104. We evaluated factors potentially associated with quantitative lipid changes from baseline to week 12. These were age, sex, race, site and baseline body mass index, CD4+ T-cell count, HIV-1 RNA level and lipids.
Results
106 participants without hyperlipidaemia at baseline started LPV/r; median age 39 years, 68% Black African, 55% female. The cumulative incidence of hyperlipidaemia at week 104 was 48% (95% CI 36, 58%). At week 12, there were significant mean increases from baseline in FTC (17 mg/dl, P<0.001) and FTG (104 mg/dl, P<0.001). In multivariable analysis, higher baseline FTC (P=0.044), FTG (P=0.025), Thai (P<0.001) or Indian sites (P=0.020) versus African sites were associated with increased risk of hyperlipidaemia.
Conclusions
In HIV-infected adults in RLS initiating LPV/r, hyperlipidaemia was common. Baseline lipid measurements and routine monitoring should be recommended in individuals starting LPV/r-based treatments with borderline high lipids.
References
1.
ShafferD., HughesM., SaweF.Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in sub-Saharan Africa: A5208 (OCTANE).J Acquir Immune Defic Syndr2014; 66: 155–163.
2.
HejaziN., RajikanR., ChoongC., SaharS.Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.BMC Public Health2013; 13: 758.
3.
GomoZ.A., HakimJ., WalkerS.Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.AIDS Res Ther2014; 11: 32.
4.
PalaciosR., SantosJ., RuizJ.Short-term lipid changes associated with highly active antiretroviral therapy in naive HIV-infected patients.J Acquir Immune Defic Syndr2003; 34: 249–251.
5.
CarrA., SamarasK., ThorisdottirA.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet1999; 353: 2093–2099.
6.
RiddlerS.A., SmitE., ColeS.Impact of HIV infection and HAART on serum lipids in men.JAMA2003; 289: 2978–2982.
7.
AbergJ.A.Cardiovascular complications in HIV management: past, present, and future.J Acquir Immune Defic Syndr2009; 50: 54–64.
8.
WHO.Consolidated Guidelines on the use of Antiretroviral Drugs for treating and preventing HIV infection: recommendations for a public health approach June 2013. (Accessed 17 December 2015.) Available from www.who.int//hiv/pub/guidelines/arv2013/en.
9.
WHO.Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. (Accessed 3 January 2016.) Available from http://www.who.int/hiv/pub/arv/adult2010/en/index.html.
10.
WalmsleyS., BernsteinB., KingM.Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection.N Engl J Med2002; 346: 2039–2046.
11.
LeeG., SeneviratneT., NoorM.The metabolic effects of lopinavir/ritonavir in HIV-negative men.AIDS2004; 18: 641–649.
12.
MadrugaJ.V., BergerD., Mc MurchieM.Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled Phase III trial.Lancet2007; 370: 49–58.
KumarasamyN., MadhavanV., VenkateshK.Lopinavir/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited settings: week 104 analysis of AIDS Clinical Trials Group (ACTG) A5230.Clin Infect Dis2015; 60: 1552–1558.
15.
BartlettJ.A., RibaudoH., WallisC.Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.AIDS2012; 26: 1345–1354.
16.
CalzaL., ManfrediR., ChiodoF.Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.J Antimicrob Chemother2004; 53: 10–14.
17.
HiransuthikulN., HiransuthikulL., KannasookY.Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.Southeast Asian J Trop Med Public Health2007; 38: 69.
18.
MontesM.L., PulidoF., BarrosC.Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.J Antimicrob Chemother2005; 55: 800–804.
19.
BongiovanniM., BiniT., CicconiP.Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.AIDS Res Hum Retroviruses2006; 22: 132–138.
20.
SinxadiP.Z., McIlleronH., DaveJ.Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study.AIDS Res Ther2012; 9: 32.
21.
GibertC.L., ShlayJ., SharmaS.Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy.J Acquir Immune Defic Syndr2009; 50: 44–53.
22.
WallisC.L., AgaE., RibaudoH.Drug susceptibility and resistance mutations after first-line failure in resource limited settings.Clin Infect Dis2014; 59: 706–715.
23.
EstradaV., PortillaJ.Dyslipidemia related to antiretroviral therapy.AIDS Rev2011; 13: 49–56.
24.
TungsiripatM., KitchD., GlesbyM.A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.AIDS2010; 24: 1781–1784.
25.
FabbianiM., BraccialeL., DoinoM.Lipid-lowering effect of tenofovir in HIV-infected patients.J Antimicrob Chemother2011; 66: 682–683.
26.
FoulkesA., WohD., FrankI.Associations among race/ ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.PLoS Med2006; 3: 0337–0347.
27.
MartínezE., DomingoP., GalindoM.Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.Clin Infect Dis2004; 38: 1017–1023.
28.
MisraA., LuthraK., VikramN.K.Dyslipidemia in Asian Indians: determinants and significance.JAPI2004; 52: 137–142.
29.
LeeD.C., XuemeiS., ChurchT.Changes in fitness and fatness on the development of cardiovascular disease risk factors: hypertension, metabolic syndrome, and hypercholesterolemia.J Am Coll Cardiol2012; 59: 665–672.
30.
CarpentierA., PattersonB., UffelmanK.Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals.Atherosclerosis2005; 178: 165–172.
31.
ShahmaneshM., DasS., StolinskiM.Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.J Clin Endocrinol Metab2005; 90: 755–760.
32.
ReedsD.N., YarasheskiK., FontanaL.Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia.Am J Physiol Endocrinol Metab2006; 290: E47–E53.
33.
LenhardJ.M., CroomD., WeielJ.Atherosclerosis and Lipoproteins: HIV protease inhibitors stimulate hepatic triglyceride synthesis.Arterioscler Thromb Vasc Biol2000; 20: 2625–2629.
34.
PetitJ.M., DuongM., DuvillardL.LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy.Eur J Clin Invest2002; 32: 354–359.
35.
LindseyC.C., GrahamM., JohnstonT.A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level.Pharmacotherapy2004; 24: 167–172.
36.
ChoiS.Y., ParkH., KimM.Difference between calculated and direct-measured low-density lipoprotein cholesterol in subjects with diabetes mellitus or taking lipid-lowering medications.J Clin Lipidol2012; 6: 114–120.
37.
La RosaA.M., HarrisonL.J., TaiwoB.Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, Phase 3, non-inferiority study.Lancet HIV2016; 3: e247–e258.
